{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:33:35Z","timestamp":1789605215537,"version":"build-2803163510"},"reference-count":33,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2023,6,26]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In experimental studies, intravitreally applied antibodies against epidermal growth factor (EGF), EGF family members (amphiregulin, neuregulin-1, betacellulin, epigen, epiregulin) and against the EGF receptor (EGFR) were associated with a reduction in lens-induced axial elongation and decrease in physiological eye elongation in guinea pigs and in non-human primates. Here, we investigated the intraocular tolerability and safety of a fully human monoclonal IgG2-antibody against EGFR, already in clinical use in oncology, as a potential future therapeutic approach for axial elongation in adult eyes with pathological myopia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinical, monocentre, open-label, multiple-dose, phase-1 study included patients with myopic macular degeneration of stage 4, who received intravitreal injections of panitumumab in various doses and in intervals ranging between 2.1 months and 6.3 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 11 patients (age:66.8\u00b16.3 years), receiving panitumumab injections in doses of 0.6\u2009mg (4 eyes; 1\u00d71 injection, 3\u00d72 injections), 1.2\u2009mg (4 eyes; 1\u00d71 injection, 2\u00d72 injections, 1\u00d73 injections) and 1.8\u2009mg (3 eyes; 1\u00d71 injection, 2\u00d72 injections), respectively. None of the participants showed treatment-emergent systemic adverse events or intraocular inflammatory reactions. Best-corrected visual acuity (1.62\u00b10.47 logarithm of the minimal angle of resolution (logMAR) vs 1.28\u00b10.59 logMAR; p=0.08) and intraocular pressure (13.8\u00b12.4\u2009mm Hg vs 14.3\u00b12.6\u2009mm Hg; p=0.20) remained unchanged. In nine patients with a follow-up of &gt;3 months (mean:6.7\u00b12.7 months), axial length did not change significantly (30.73\u00b11.03\u2009mm vs 30.77\u00b11.19\u2009mm; p=0.56).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this open-labelled, phase-1 study with a mean follow-up of 6.7 months, panitumumab repeatedly administered intravitreally up to a dose of 1.8\u2009mg was not associated with intraocular or systemic adverse effects. During the study period, axial length remained unchanged.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>DRKS00027302.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjo-2023-323383","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T11:30:14Z","timestamp":1689593414000},"page":"859-864","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Intravitreal panitumumab and myopic macular degeneration"],"prefix":"10.1136","volume":"108","author":[{"given":"Mukharram M","family":"Bikbov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyulli M","family":"Kazakbaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhomitra","family":"Panda-Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leisan I","family":"Gilemzianova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinar A","family":"Khakimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2972-5227","authenticated-orcid":false,"given":"Jost B","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"2024052109250907000_108.6.859.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.01.006"},{"key":"2024052109250907000_108.6.859.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60272-4"},{"key":"2024052109250907000_108.6.859.3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/09286586.2001.11644261","article-title":"Visual impairment in a Taiwanese population: prevalence, causes, and socioeconomic factors","volume":"8","author":"Liu","year":"2001","journal-title":"Ophthalmic Epidemiol"},{"key":"2024052109250907000_108.6.859.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.05.011"},{"key":"2024052109250907000_108.6.859.5","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2006.01.035","article-title":"Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing eye study","volume":"113","author":"Xu","year":"2006","journal-title":"Ophthalmology"},{"key":"2024052109250907000_108.6.859.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.11.003"},{"key":"2024052109250907000_108.6.859.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.06.050"},{"key":"2024052109250907000_108.6.859.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.12.005"},{"key":"2024052109250907000_108.6.859.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.01.035"},{"key":"2024052109250907000_108.6.859.10","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaophthalmol.2020.2211","article-title":"Five-year incidence of myopic maculopathy in a general Japanese population: the Hisayama study","volume":"138","author":"Ueda","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"2024052109250907000_108.6.859.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.05.009"},{"key":"2024052109250907000_108.6.859.12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00417-012-2066-9","article-title":"Changes of axial length measured by IOL master during 2 years in eyes of adults with pathologic myopia","volume":"251","author":"Saka","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2024052109250907000_108.6.859.13","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-314619"},{"key":"2024052109250907000_108.6.859.14","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1001\/jamaophthalmol.2021.3303","article-title":"Continued increase of axial length and its risk factors in adults with high myopia","volume":"139","author":"Du","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"2024052109250907000_108.6.859.15","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001464"},{"key":"2024052109250907000_108.6.859.16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/01.APO.0000578944.25956.8b","article-title":"Anatomic changes and consequences for its etiology","volume":"8","author":"Jonas","year":"2019","journal-title":"Asia-Pacific Journal of Ophthalmology"},{"key":"2024052109250907000_108.6.859.17","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(91)90233-P"},{"key":"2024052109250907000_108.6.859.18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0014-4835(92)90122-9","article-title":"Epidermal growth factor potentiates the transmitter-induced stimulation of C-AMP and inositol phosphates in human pigment epithelial cells in culture","volume":"55","author":"Liu","year":"1992","journal-title":"Exp Eye Res"},{"key":"2024052109250907000_108.6.859.19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ebiom.2017.02.021","article-title":"Amphiregulin antibody and reduction of axial elongation in experimental myopia","volume":"17","author":"Jiang","year":"2017","journal-title":"EBioMedicine"},{"key":"2024052109250907000_108.6.859.20","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1111\/aos.14080","article-title":"Amphiregulin and ocular axial length","volume":"97","author":"Dong","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"2024052109250907000_108.6.859.21","doi-asserted-by":"crossref","first-page":"13654","DOI":"10.1096\/fj.202001095RR","article-title":"Blockade of epidermal growth factor and its receptor and axial elongation in experimental myopia","volume":"34","author":"Dong","year":"2020","journal-title":"FASEB J"},{"key":"2024052109250907000_108.6.859.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-022-02417-8","article-title":"Epiregulin, epigen and betacellulin antibodies and axial elongation in young guinea pigs with lens-induced Myopization","volume":"22","author":"Dong","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"2024052109250907000_108.6.859.23","doi-asserted-by":"crossref","unstructured":"Wang W , Nan Y , Huang T , et al . Intraocular amphiregulin antibody and axial elongation in nonhuman primates. Front Ophthalmol 2022;2. doi:10.3389\/fopht.2022.995157","DOI":"10.3389\/fopht.2022.995157"},{"key":"2024052109250907000_108.6.859.24","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1007\/s00417-021-05200-5","article-title":"Intraocular epidermal growth factor concentration, axial length, and high axial myopia","volume":"259","author":"Jonas","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2024052109250907000_108.6.859.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305275"},{"key":"2024052109250907000_108.6.859.26","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1337"},{"key":"2024052109250907000_108.6.859.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.01.022"},{"key":"2024052109250907000_108.6.859.28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10633-022-09872-0","article-title":"ISCEV standard for full-field clinical electroretinography (2022 update)","volume":"144","author":"Robson","year":"2022","journal-title":"Doc Ophthalmol"},{"key":"2024052109250907000_108.6.859.29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40942-019-0157-z","article-title":"Anterior chamber paracentesis during intravitreal injections in observational trials: effectiveness and safety and effects","volume":"5","author":"Saxena","year":"2019","journal-title":"Int J Retin Vitr"},{"key":"2024052109250907000_108.6.859.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"2024052109250907000_108.6.859.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"2024052109250907000_108.6.859.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011"},{"key":"2024052109250907000_108.6.859.33","doi-asserted-by":"publisher","DOI":"10.1080\/08830180212066"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2023-323383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T16:29:41Z","timestamp":1716308981000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2023-323383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/bjo-2023-323383"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2023-323383","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]}}}